Skip Navigation

Cardiovascular Research 1999 42(1):15-26; doi:10.1016/S0008-6363(99)00004-8
© 1999 by European Society of Cardiology
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Flores, N. A.
Right arrow Articles by Sheridan, D. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Flores, N. A.
Right arrow Articles by Sheridan, D. J.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Copyright © 1999, European Society of Cardiology

The effects of diadenosine polyphosphates on the cardiovascular system

Nicholas A. Flores*, Brigitte M. Stavrou and Desmond J. Sheridan

Academic Cardiology Unit, National Heart and Lung Institute, Imperial College School of Medicine, London W2 1NY, UK

n.flores{at}ic.ac.uk

* Corresponding author. Tel.: +44-171-886-6129/6267; fax: +44-171-886-6732

Diadenosine polyphosphates are members of a group of dinucleoside polyphosphates that are ubiquitous, naturally occurring molecules. They form a recently identified class of compounds derived from ATP and consist of two adenosine molecules bridged by up to six phosphate groups. These compounds are stored in high concentrations in platelet dense granules and are released when platelets become activated. Some of the compounds promote platelet aggregation, while others are inhibitory. Possible roles as neurotransmitters, extracellular signalling molecules or ‘alarmones’ secreted by cells in response to physiologically stressful stimuli have been postulated. Recent studies suggest a role for these compounds in atrial and synaptic neurotransmission. Studies using isolated mesenteric arteries indicate an important role of phosphate chain length in determining whether diadenosine polyphosphates produce vasodilatation or vasoconstriction, but in the coronary circulation, diadenosine polyphosphates generally produce vasodilatation via mechanisms thought to involve release of NO or prostacyclin (PGI2). They produce cardiac electrophysiological effects by altering ventricular refractoriness at submicromolar concentrations and reduce heart rate. Mechanisms involving KATP channels have been proposed in addition to the involvement of P1- and P2-purinergic receptors and the specific diadenosine polyphosphate receptor identified on isolated cardiac myocytes. Clinical evidence suggests a role for diadenosine polyphosphates in hypertensive patients and those with the Chédiak–Higashi syndrome. This review outlines the effects of these compounds on the cardiovascular system and considers their potential involvement in mediating the pathophysiological effects associated with platelet activation during myocardial ischaemia.

KEYWORDS Vasoconstriction/dilation; Bradycardia; K-ATP channel; Platelets; Haemodynamics


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Cardiovasc ResHome page
A. L. Garcia-Villalon, L. Monge, N. Fernandez, A. Salcedo, R. Narvaez-Sanchez, and G. Dieguez
Coronary response to diadenosine pentaphosphate after ischaemia-reperfusion in the isolated rat heart
Cardiovasc Res, February 1, 2009; 81(2): 336 - 343.
[Abstract] [Full Text] [PDF]

Home page
 HypertensionHome page
J. Luo, V. Jankowski, N. Gungar, J. Neumann, W. Schmitz, W. Zidek, H. Schluter, and J. Jankowski
Endogenous Diadenosine Tetraphosphate, Diadenosine Pentaphosphate, and Diadenosine Hexaphosphate in Human Myocardial Tissue
Hypertension, May 1, 2004; 43(5): 1055 - 1059.
[Abstract] [Full Text] [PDF]

Home page
 Nephrol Dial TransplantHome page
M. Steinmetz, G. Gabriels, T. V. Le, H.-J. Piechota, K. H. Rahn, and E. Schlatter
Vasoactivity of diadenosine polyphosphates in human small renal resistance arteries
Nephrol. Dial. Transplant., December 1, 2003; 18(12): 2496 - 2504.
[Abstract] [Full Text] [PDF]

Home page
 Arterioscler. Thromb. Vasc. Bio.Home page
J. Jankowski, V. Jankowski, U. Laufer, M. van der Giet, L. Henning, M. Tepel, W. Zidek, and H. Schluter
Identification and Quantification of Diadenosine Polyphosphate Concentrations in Human Plasma
Arterioscler Thromb Vasc Biol, July 1, 2003; 23(7): 1231 - 1238.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
T. Westhoff, J. Jankowski, S. Schmidt, J. Luo, G. Giebing, H. Schluter, M. Tepel, W. Zidek, and M. van der Giet
Identification and Characterization of Adenosine 5'-Tetraphosphate in Human Myocardial Tissue
J. Biol. Chem., May 9, 2003; 278(20): 17735 - 17740.
[Abstract] [Full Text] [PDF]

Home page
 Cardiovasc ResHome page
G. Gabriels, K. H. Rahn, E. Schlatter, and M. Steinmetz
Mesenteric and renal vascular effects of diadenosine polyphosphates (APnA)
Cardiovasc Res, October 1, 2002; 56(1): 22 - 32.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
M. Steinmetz, A.-K. Janssen, F. Pelster, K. H. Rahn, and E. Schlatter
Vasoactivity of Diadenosine Polyphosphates in Human Small Mesenteric Resistance Arteries
J. Pharmacol. Exp. Ther., August 1, 2002; 302(2): 787 - 794.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
B. M. Stavrou, D. J. Sheridan, and N. A. Flores
Contribution of Nitric Oxide and Prostanoids to the Cardiac Electrophysiological and Coronary Vasomotor Effects of Diadenosine Polyphosphates
J. Pharmacol. Exp. Ther., August 1, 2001; 298(2): 531 - 538.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Renal Physiol.Home page
E. W. Inscho
P2 receptors in regulation of renal microvascular function
Am J Physiol Renal Physiol, June 1, 2001; 280(6): F927 - F944.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.